Nicotinell Spearmint (Nicotine Polacrilex)

Nicotine Polacrilex, the active ingredient in Nicotinell Spearmint, is a nicotine replacement therapy presented as a buccal formulation for buccal use. It helps adult smokers who wish to quit by reducing nicotine withdrawal symptoms and cravings. GNH USA supplies Nicotinell Spearmint as a licensed, GDP-compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Nicotinell Spearmint is a nicotine replacement therapy used in smoking cessation.

Smoking cessation: assists adult smokers in reducing withdrawal symptoms and cravings during quit attempts. Tobacco dependence: supports gradual reduction of nicotine intake for individuals dependent on tobacco. Relapse prevention: helps maintain abstinence after an initial quit attempt by providing controlled nicotine exposure.

Nicotinell Spearmint may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Mouth irritation or soreness - Throat irritation or dryness - Nausea or mild gastrointestinal discomfort - Increased salivation or hiccups

Serious or Rare Side Effects: - Allergic reactions such as rash, swelling, or itching - Dizziness or light‑headedness - Chest pain or palpitations - Severe mouth ulceration or anaphylaxis

When using Nicotinell Spearmint, consider the following safety measures.

Cardiovascular assessment: evaluate patients with known heart disease before initiating therapy. Medical supervision: use under the guidance of a healthcare professional, especially for first‑time quitters. Non‑smokers: the product is not intended for individuals who do not currently use tobacco. Concurrent nicotine products: avoid using other nicotine replacement therapies simultaneously to prevent overdose. Pregnancy and lactation: safety has not been established; consult a physician before use. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Nicotinell Spearmint can interact with other substances that affect nicotine levels or cardiovascular function.

Major Interactions (Avoid): - Concurrent use of other nicotine replacement products: risk of nicotine toxicity. - Use with monoamine oxidase inhibitors (MAOIs): potential for hypertensive reactions.

Moderate Interactions (Monitor Closely): - CYP2A6 inhibitors (e.g., certain antifungals): may increase nicotine plasma concentrations. - Beta‑blockers: nicotine‑induced tachycardia may be masked. - Certain antidepressants (e.g., SSRIs): may alter nicotine metabolism and affect efficacy.